Coronado Biosciences announces Phase 2 study evaluating TSO in UC

Coronado Biosciences announced the signing of a Clinical Trial Agreement between the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health (NIH), and Coronado Biosciences to evaluate TSO, or Trichuris suis ova or CNDO-201, for the treatment of ulcerative colitis, or UC, in a phase 2 clinical trial. This multi-center study will be conducted by the NIAID-funded Autoimmunity Centers of Excellence.

View Comments (0)